How are energy investors positioned?
BURLINGTON, MA – Trent (NSE:TREN) Kamke, Senior Vice President of Operations at LeMaitre Vascular Inc . (NASDAQ:LMAT), recently sold shares totaling $525,052, according to a Form 4 filing with the Securities and Exchange Commission. The transactions occurred between March 12 and March 13, 2025, with sale prices ranging from $79.589 to $82.12 per share. The sales come as the $1.84 billion market cap company shows strong financial health, according to InvestingPro analysis, despite a 14.25% decline in stock price year-to-date.
On March 12, Kamke sold 2,009 shares at $82.12 each. The following day, he sold an additional 4,520 shares, with prices ranging from $79.08 to $80.34 per share.
In addition to these sales, Kamke exercised stock options, acquiring 3,588 shares at prices between $23.56 and $48.60, totaling $147,338. These transactions reflect Kamke’s continued activity in managing his equity holdings in the company.
LeMaitre Vascular, based in Burlington (NYSE:BURL), Massachusetts, specializes in surgical and medical instruments and apparatus, serving the healthcare industry with innovative solutions. The company maintains a strong financial position with a GREAT overall health score. For detailed insights and a comprehensive analysis of LMAT’s valuation and growth prospects, access the full InvestingPro Research Report, available exclusively to subscribers.
In other recent news, LeMaitre Vascular has reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $0.49, which exceeded the forecast of $0.46. The company also reported revenues of $55.7 million, marking a 14% year-over-year increase and slightly exceeding the projections of $55.49 million. JMP Securities responded by raising its price target for LeMaitre to $113, noting the company’s consistent financial performance and strategic initiatives. Meanwhile, Barrington Research downgraded LeMaitre from Outperform to Market Perform, citing concerns over the stock’s valuation following a significant price increase since May 2023.
Oppenheimer also downgraded the company’s stock rating from Outperform to Perform after the earnings report, expressing concerns about the sustainability of price increases contributing to LeMaitre’s premium valuation. Despite these downgrades, LeMaitre’s strong execution was highlighted, with plans to expand its sales force and continue international growth, including the approval of XenoSure in China. For fiscal year 2025, LeMaitre introduced revenue guidance between $235.4 million and $242.8 million, which is slightly below some analyst expectations. The company remains focused on strategic growth, with plans to hire additional sales representatives and expand its market presence in North America and internationally.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.